3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Conditions
Breast Neoplasms
235
Neoplasms
207
Carcinoma, Non-Small-Cell Lung
101
Colorectal Neoplasms
99
Prostatic Neoplasms
93
Lung Neoplasms
78
Multiple Myeloma
53
Melanoma
52
Pancreatic Neoplasms
50
Head and Neck Neoplasms
50
Neoplasm Metastasis
48
Leukemia, Myeloid, Acute
44
Carcinoma, Hepatocellular
43
Ovarian Neoplasms
39
Brain Neoplasms
39
Squamous Cell Carcinoma of Head and Neck
37
Recurrence
37
Glioblastoma
33
Uterine Cervical Neoplasms
32
Glioma
31
Sarcoma
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Stomach Neoplasms
28
Lymphoma, Non-Hodgkin
28
Lymphoma
27
Colonic Neoplasms
27
Carcinoma, Renal Cell
26
Lymphoma, Follicular
25
Esophageal Neoplasms
24
Rectal Neoplasms
23
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Amyloid Neuropathies, Familial
×
90 days
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled
NCT03431896
2026-03-12
MED-hATTR
The Cleveland Clinic
Completed
37 enrolled